Induction chemotherapy in the management of squamous cell carcinoma of the head and neck

References

• Forastiere A, Koch W, Trotti A, Sidransky D. Head and neck cancer. N. Engl. J. Med.345(26), 1890–1900 (2001).
   PubMed Web of Science ®Google Scholar
• Posner MR, Haddad RI, Wirth L et al. Induction chemotherapy in locally advanced squamous cell cancer of the head and neck: evolution of the sequential treatment approach. Semin. Oncol.31(6), 778–785 (2004).
   PubMed Web of Science ®Google Scholar
• Forastiere AA, Goepfert H, Maor M et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N. Engl. J. Med.349(22), 2091–2098 (2003).
   PubMed Web of Science ®Google Scholar
• Lefebvre JL, Chevalier D, Luboinski B, Kirkpatrick A, Collette L, Sahmoud T. Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer Phase III trial. EORTC Head and Neck Cancer Cooperative Group. J. Natl Cancer Inst.88(13), 890–899 (1996).
   PubMed Web of Science ®Google Scholar
• The Department of Veterans Affairs Laryngeal Cancer Study Group. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N. Engl. J. Med.324(24), 1685–1690 (1991).
   PubMed Web of Science ®Google Scholar
• Al-Sarraf M, LeBlanc M, Giri PG et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: Phase III randomized Intergroup study 0099. J. Clin. Oncol.16, 1310–1317 (1998).
   PubMed Web of Science ®Google Scholar
• Domenge C, Hill C, Lefebvre JL et al. Randomized trial of induction chemotherapy in oropharyngeal carcinoma. French Groupe d’Etude des Tumeurs de la Tete et du Cou (GETTEC). Br. J. Cancer.83(12), 1594–1598 (2000).
   PubMed Web of Science ®Google Scholar
• Calais G, Alfonsi M, Bardet E et al. Randomized trial of radiation therapy versus concomitant chemoradiotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J. Natl Cancer Inst.91(24), 2081–2086 (1999).
   PubMed Web of Science ®Google Scholar
• Argiris A. Update on chemoradiotherapy for head and neck cancer. Curr. Opin. Oncol.14(3), 323–329 (2002).
   PubMedGoogle Scholar
• Hitt R, Lopez-Pousa A, Rodriguez M et al. Phase III study comparing cisplatin (P) and 5-fluorouracil (F) versus P, F, and paclitaxel (T) as induction therapy in locally advanced head and neck cancer (LAHNC). Proceedings of the 39th Annual Meeting of the Am. Soc. Clin.Oncol. Chicago, IL, USA (2003) (Abstr. 1997).
   Google Scholar
• El-Sayed S, Nelson N. Adjuvant and adjunctive chemotherapy in the management of squamous cell carcinoma of the head and neck region. A meta-analysis of prospective and randomized trials. J. Clin. Oncol.14, 838–847 (1996).
   PubMed Web of Science ®Google Scholar
• Munro AJ. An overview of randomized controlled trials of adjuvant chemotherapy in head and neck cancer. Br. J. Cancer.71(1), 83–91 (1995).
   PubMed Web of Science ®Google Scholar
• Pignon JP, Bourhis J, Domenge C, Designe L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet355(9208), 949–955 (2000).
   PubMed Web of Science ®Google Scholar
• Posner MR. Paradigm shift in the treatment of head and neck cancer: the role of induction chemotherapy.Oncologist10(Suppl. 3), 11–19 (2005).
   PubMed Web of Science ®Google Scholar
• Posner MR, Lefebvre JL. Docetaxel induction therapy in locally advanced squamous cell carcinoma of the head and neck. Br. J. Cancer.88, 11–17 (2003).
   PubMed Web of Science ®Google Scholar
• Colevas AD, Norris CM, Tishler RB et al. Phase II trial of docetaxel, cisplatin, fluorouracil, and leucovorin as induction for squamous cell carcinoma of the head and neck. J. Clin. Oncol.17(11), 3503–3511 (1999).
   PubMed Web of Science ®Google Scholar
• Colevas AD, Norris CM, Tishler RB et al. Phase I/II trial of outpatient docetaxel, cisplatin, 5-fluorouracil, leucovorin (opTPFL) as induction for squamous cell carcinoma of the head and neck (HNSCC). Am. J. Clin. Oncol.25(2), 153–159 (2002).
   PubMed Web of Science ®Google Scholar
• Colevas AD, Busse PM, Norris CM et al. Induction chemotherapy with docetaxel, cisplatin, fluorouracil, and leucovorin for squamous cell carcinoma of the head and neck: a Phase I/II trial. J. Clin. Oncol.16, 1331–1339 (1998).
   PubMedGoogle Scholar
• Zorat PL, Paccagnella A, Cavaniglia G et al. Randomized Phase III trial of induction chemotherapy in head and neck cancer: 10-year follow-up. J. Natl Cancer Inst.96(22), 1714–1717 (2004).
   PubMed Web of Science ®Google Scholar
• Jeremic B, Shibamoto Y, Milicic B et al. Hyperfractionated radiation therapy with or without concurrent low-dose daily cisplatin in locally advanced squamous cell carcinoma of the head and neck: a prospective randomized trial. J. Clin. Oncol.18(7), 1458–1464 (2000).
   PubMed Web of Science ®Google Scholar
• Forastiere AA, Maor M, Weber RS et al. Long-term results of Intergroup RTOG 91–11: A Phase III trial to preserve the larynx – induction cisplatin/5-FU and radiation therapy versus concurrent cisplatin and radiation therapy versus radiation therapy. Proceedings of the 42nd Annual Meeting of the Am. Soc. Clin. Oncol. Atlanta, GA, USA (2006) (Abstract 5517).
   Google Scholar
• Paccagnella A, Orlando A, Marchiori C et al. Phase III trial of initial chemotherapy in stage III or IV head and neck cancers: a study by the Gruppo di Studio sui Tumori della Testa e del Collo. J. Natl Cancer Inst.86(4), 265–272 (1994).
   PubMed Web of Science ®Google Scholar
• Couteau C, Chouaki N, Leyvraz S et al. A Phase II study of docetaxel in patients with metastatic squamous cell carcinoma of the head and neck. Br. J. Cancer.81(3), 457–462 (1999).
   PubMed Web of Science ®Google Scholar
• Dreyfuss AI, Clark JR, Norris CM et al. Docetaxel: an active drug for squamous cell carcinoma of the head and neck. J. Clin. Oncol.14, 1672–1678 (1996).
   PubMed Web of Science ®Google Scholar
• Catimel G, Verweij J, Mattijssen V et al. Docetaxel (Taxotere): an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group. Ann. Oncol.5, 533–537 (1994).
   PubMed Web of Science ®Google Scholar
• Posner M, Glisson B, Frenette G et al. Multicenter Phase I–II trial of docetaxel, cisplatin, and fluorouracil induction chemotherapy for patients with locally advanced squamous cell cancer of the head and neck. J. Clin. Oncol.19(4), 1096–1104 (2001).
   PubMed Web of Science ®Google Scholar
• Schrijvers D, Van Herpen C, Kerger J et al. Docetaxel, cisplatin and 5-fluorouracil in patients with locally advanced unresectable head and neck cancer: a Phase I–II feasibility study. Ann. Oncol.15, 638–645 (2004).
   PubMedGoogle Scholar
• Watanabe A, Taniguchi M, Sasaki S. Induction chemotherapy with docetaxel, cisplatin, fluorouracil and l-leucovorin for locally advanced head and neck cancers: a modified regimen for Japanese patients. Anticancer Drugs14(10), 801–807 (2003).
   PubMedGoogle Scholar
• Pignon JP, Syz N, Posner M et al. Adjusting for patient selection suggests the addition of docetaxel to 5-fluorouracil–cisplatin induction therapy may offer survival benefit in squamous cell cancer of the head and neck. Anticancer Drugs15(4), 331–340 (2004).
   PubMed Web of Science ®Google Scholar
• Vermorken JB, Remenar E, Van Herpen C et al. Standard cisplatin/infusional 5-fluorouracil (PF) vs docetaxel (T) plus PF (TPF) as induction chemotherapy for nonresectable locally advanced squamous cell carcinoma of the head and neck (LA-HNSCC): a Phase III trial of the EORTC Head and Neck Cancer Group (EORTC, 24971). Proceedings of the 40th Annual Meeting of the Am. Soc. Clin. Oncol. New Orleans, LA, USA (2004) (abstract 5508).
   Google Scholar
• Remenar E, Van Herpen C, Germa Lluch J et al. A randomized Phase III multicenter trial of neoadjuvant docetaxel plus cisplatin and 5-fluorouracil (TPF) versus neoadjuvant PF in patients with locally advanced unresectable squamous cell carcinoma of the head and neck (SCCHN). Final Analysis of EORTC 24971. Proceedings of the 42nd Annual Meeting of the Am. Soc. of Clin. Oncol. Atlanta, GA, USA (2006) (abstract 5516).
   Google Scholar
• Forastiere AA, Shank D, Neuberg D, Taylor SG 4th, DeConti RC, Adams G. Final report of a Phase II evaluation of paclitaxel in patients with advanced squamous cell carcinoma of the head and neck: an Eastern Cooperative Oncology Group trial (PA390). Cancer82(11), 2270–2274 (1998).
   PubMed Web of Science ®Google Scholar
• Hitt R, Paz-Ares L, Brandariz A et al. Induction chemotherapy with paclitaxel, cisplatin and 5-fluorouracil for squamous cell carcinoma of the head and neck: long-term results of a Phase II trial. Ann. Oncol.13, 1665–1673 (2002).
   PubMedGoogle Scholar
• Hitt R, Jimeno A, Millan JM, Castellano D, Cortes-Funes H. Phase II trial of dose-dense paclitaxel, cisplatin, 5-fluorouracil, and leucovorin with filgrastim support in patients with squamous cell carcinoma of the head and neck. Cancer101(4), 768–775 (2004).
   PubMedGoogle Scholar
• Gibson MK, Li Y, Murphy B et al. Randomized Phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an Intergroup trial of the Eastern Cooperative Oncology Group. J. Clin. Oncol.23(15), 3562–3567 (2005).
   PubMed Web of Science ®Google Scholar
• Shin DM, Glisson BS, Khuri FR et al. Phase II study of induction chemotherapy with paclitaxel, ifosfamide, and carboplatin (TIC) for patients with locally advanced squamous cell carcinoma of the head and neck. Cancer95(2), 322–330 (2002).
   PubMed Web of Science ®Google Scholar
• Pai VR, Mazumdar AT, Deshmukh et al. Induction chemotherapy with ifosfamide and cisplatin combination in advanced head and neck cancer: a retrospective analysis of 519 patients: a single institution experience. Med. Oncol.20(1), 1–5 (2003).
   PubMedGoogle Scholar
• Adelstein DJ, Li Y, Adams GL et al. An intergroupPhase III comparison of radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J. Clin. Oncol.21(1), 92–98 (2003).
   PubMed Web of Science ®Google Scholar
• Adelstein DJ, Saxton JP, Lavertu P et al. Maximizing local control and organ preservation in stage IV squamous cell head and neck cancer with hyperfractionated radiation and concurrent chemotherapy. J. Clin. Oncol.20(5), 1405–1410 (2002).
   PubMed Web of Science ®Google Scholar
• Argiris A, Haraf DJ, Kies MS, Vokes EE. Intensive concurrent chemoradiotherapy for head and neck cancer with 5-fluorouracil- and hydroxyurea-based regimens: reversing a pattern of failure. Oncologist8(4), 350–360 (2003).
   PubMed Web of Science ®Google Scholar
• Vokes EE, Stenson K, Rosen FR et al. Weekly carboplatin and paclitaxel followed by concomitant paclitaxel, fluorouracil, and hydroxyurea chemoradiotherapy: curative and organ-preserving therapy for advanced head and neck cancer. J. Clin. Oncol.21(2), 320–326 (2003).
   PubMed Web of Science ®Google Scholar
• Urba SG, Moon J, Giri PG et al. Organ preservation for advanced resectable cancer of the base of tongue and hypopharynx: a Southwest Oncology Group Trial. J. Clin. Oncol.23(1), 88–95 (2005).
   PubMed Web of Science ®Google Scholar
• Haraf DJ, Rosen FR, Stenson K et al. Induction chemotherapy followed by concomitant TFHX chemoradiotherapy with reduced dose radiation in advanced head and neck cancer. Clin. Cancer Res.9(16 Pt 1), 5936–5943 (2003).
   PubMed Web of Science ®Google Scholar
• Urba S, Wolf G, Eisbruch A et al. Single-cycle induction chemotherapy selects patients with advanced laryngeal cancer for combined chemoradiation: a new treatment paradigm. J. Clin. Oncol.24(4), 593–598 (2006).
   PubMed Web of Science ®Google Scholar
• Machtay M, Rosenthal DI, Hershock D et al. Organ preservation therapy using induction plus concurrent chemoradiation for advanced resectable oropharyngeal carcinoma: a University of Pennsylvania Phase II trial. J. Clin. Oncol.20(19), 3964–3971 (2002).
   PubMed Web of Science ®Google Scholar
• Hainsworth JD, Meluch AA, McClurkan S et al. Induction paclitaxel, carboplatin, and infusional 5-FU followed by concurrent radiation therapy and weekly paclitaxel/carboplatin in the treatment of locally advanced head and neck cancer: a Phase II trial of the Minnie Pearl Cancer Research Network. Cancer J.8(4), 311–321 (2002).
   PubMedGoogle Scholar
• Cmelak A, Murphy BA, Burkey B, Douglas S, Netterville J. Induction chemotherapy (IC) followed by concurrent chemoradiation (CCR) for organ preservation (OP) in locally advanced squamous head and neck cancer (SHNC): results of a Phase II trial. Proceedings of the 39th Annual Meeting of the Am. Soc. Clin.Oncol. Chicago, IL, USA (2003) (Abstract 2016).
   Google Scholar
• Rathore R, Chougule P, Wanebo H et al. Phase II study of induction weekly paclitaxel, ifosfamide, and carboplatin (PIC) followed by chemoradiotherapy (CRT) in locally advanced head and neck squamous cell cancer (HNSCC): a Brown University Oncology Group study (HN-86). Proceedings of the 41st Annual Meeting of the Am. Soc. Clin. Oncol. Orlando, FL, USA (2005) (Abstract 5556).
   Google Scholar
• Haddad R, Tishler RB, Norris CM et al. Docetaxel, cisplatin, 5-fluorouracil (TPF)-based induction chemotherapy for head and neck cancer and the case for sequential, combined-modality treatment. Oncologist8(1), 35–44 (2003).
   PubMed Web of Science ®Google Scholar
• Pfister DG, Su YB, Kraus DH et al. Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm. J. Clin. Oncol.24(7), 1072–1078 (2006).
   PubMed Web of Science ®Google Scholar
• Shi-Long Lu, Herrington H, Reh D et al. Deletion of TGFβ type II receptor leads to metastatic head-and-neck squamous cell carcinoma. Proceedings of the 97th Annual Meeting of Am. Assoc. Cancer Res. Washington, DC, USA, 63 (2006) (Abstract 266).
   Google Scholar
• Kupferman ME, Zhou G, Zhao M et al. A novel inhibitor of STAT3 signaling in head and neck squamous cell carcinoma. Proceedings of the 97th Annual Meeting of Am. Assoc. Cancer Res. Washington, DC, USA, 571 (2006) (Abstr. 2413).
   Google Scholar
• Bonner JA, Harari PM, Giralt J et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N. Engl. J. Med.354(6), 567–578 (2006).
   PubMed Web of Science ®Google Scholar
• Bozec A, Formento P, Fischel J-L, Hofman P, Etienne M-C, Milano G. Combined effect of EGFR targeting with antiangiogenesis and irradiation. Proceedings of the 97th Annual Meeting of Am. Assoc. Cancer Res. Washington, DC, USA, 55 (2006) (Abstr. 232).
   Google Scholar
• Warner GC, Reis PP, Jurisica I et al. Molecular classification of oral cancer by cDNA microarrays identifies overexpressed genes correlated with nodal metastasis. Int. J. Cancer110(6), 857–868 (2004).
   PubMed Web of Science ®Google Scholar
• Dysvik B, Vasstrand EN, Lovlie R et al. Gene expression profiles of head and neck carcinomas from Sudanese and Norwegian patients reveal common biological pathways regardless of race and lifestyle. Clin. Cancer Res.12(4), 1109–1120 (2006).
   PubMedGoogle Scholar
• Lee S, Yin X, Shores C, Hayes DN. Cross platform validation of head and neck squamous cell carcinoma tumor subtypes found by expression profiling. Proccedings of the 97th Annual Meeting of Am. Assoc. Cancer Res. Washington, DC, USA, 200 (2006) (abstract 850).
   Google Scholar
• Cazares LH, Green-Mitchell S, Vokes EE et al. Proteomic profiles predict therapy response in patients with squamous cell carcinoma of the head and neck. Proceedings of the 97th Annual Meeting of Am. Assoc. Cancer Res. Washington, USA, 672 (2006) (abstract 2862).
   Google Scholar
• Chin D, Boyle GM, Williams RM et al. Novel markers for poor prognosis in head and neck cancer. Int. J. Cancer113(5), 789–797 (2005).
   PubMed Web of Science ®Google Scholar